Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Looks a bit toppy to me.

;-)

Ignore Al .... wind up merchant

:-)

News Article
Operational Board Update and Appointment

01/02/2007

London, UK, 1 February 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company, today announces the creation of a new executive operational board for the Company, and the appointment of Keith Hemming, as Head of Operations, a new position within the management team of BioProgress.

The operational board will be responsible for the day to day management of the Group. This has become necessary as the number of new development projects both for partners and for the Company's own pharmaceutical division is increasing substantially due to positive validation work and the adoption of a number of BioProgress"s enabling systems. At the same time the core pharmaceutical division Dexo is undergoing rapid growth in all of its territories. This underlying organic growth validates the Companys product led strategy and creates the resource necessary for continued substantial growth.

Keith Hemming, the new Head of Operations, has over twenty years experience in the Pharmaceutical industry, holding senior marketing and General Management positions with Squibb, Yamanouchi, and most recently as President UK Operations for Fujisawa Pharma, member of the Fujisawa European senior management team. Prior to this he was with Astellas Pharmaceuticals Global Licensee Division working on European strategy and implementation. During his career he launched Flomax and Protopic in the UK, and took Prograf, an immunosuppressant, to market leadership.

Keith was a member of the Board of Management of the Association of British Pharmaceutical Industry (ABPI) for four years, and member of the UK Pharmaceutical Code of Practice Appeal Board.

He was also founder and first Chair of the UK Japanese Pharmaceutical Group associated to the Japanese Pharmaceutical Manufacturers Association (JPMA), and Chair of the Industry Group for the National Health Service Framework for Renal Services.

Richard Trevillion, Chief Executive Officer, BioProgress Plc, said:

"We are pleased to welcome Keith to the operational management team. Keith has substantial experience in sales and marketing and in managing high growth late stage pharmaceutical product development. His knowledge of the Japanese pharmaceutical industry is also welcome as BioProgress increases its marketing activity within Japan.

Keith Hemming, Head of Operations, said:

I am delighted to be joining BioProgress at such an exciting stage in the Companys development. The recent increase in activity is testament to the strength of the core enabling systems which are contributing to a strong product development pipeline. The resulting rapid growth in the Dexo pharmaceutical sales and marketing division validates the product led speciality pharmaceutical model that BioProgress is proactively pursuing.

This company seems to be heading in the right direction at last.
kim

BioProgress PLC
07 March 2007

For Immediate Release

BioProgress plc

BioProgress (DEXO) Agreement to Promote Accuhist(R) Product Line in U.S.

London, UK, 7 March 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM:
BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company, is
pleased to announce the completion of an agreement with Tiber Laboratories to
promote the Accuhist(R) line of pediatric drops throughout the United States.

The company will be responsible for sales and promotion of three well-known
products - Accuhist Pediatric Drops, Accuhist(R) PDX Drops, and Accuhist(R) DM
Drops. The products compete in the growing category of cough/cold drops for
infants, a market currently in excess of $2 billion. The Accuhist(R) line was
sold nationally by PediaMed in the years prior to the sale to Tiber
Laboratories. In recent years the Accuhist(R) line held the number two position
in share of the key US market. The new agreement between Tiber Laboratories and
DEXO, BioProgress' U.S. pharmaceutical subsidiary, will reestablish promotion of
this widely prescribed product.

In addition, BioProgress will develop for Tiber Laboratories a film strip
version of the popular Accuhist(R) product which is scheduled for launch in H2
2007. The product will be promoted by Tiber Laboratories with a development
royalty on sales paid to BioProgress' manufacturing subsidiary BioTec Films.
The tremendous growth of film strips as a convenient means of patient dosing is
changing the face of medicine, and Tiber Laboratories anticipates the film strip
becoming an integral part of their product offering.

Specifically, BioProgress will realise 50% of the sales of the Accuhist(R)
Pediatric, PDX and DM drops for a period beginning shortly after the date of
this agreement and a further 10% Royalty based on gross sales of the film strip
version of Accuhist(R). BioProgress will also have the opportunity to realize up
to 80% of the sales of Accuhist(R) Pediatric, PDX and DM drops once various
milestones have been achieved regarding the sales of the film strip product.

BioProgress continues the aggressive development of products for the pediatric
market. This agreement adds pediatric drop products to the portfolio,
augmenting the existing array of products including brands such as Ah-Chew(R)
and E-Z Spacer(R). The company has several new products in development
including an orally dissolving tablet, and several films version of the Ah-Chew
line.

Richard Trevillion, Chief Executive Officer, of BioProgress commented:

'The Accuhist(R) line is a high profile U.S. brand that will add depth to our
growing U.S. portfolio. The Accuhist(R) product is a prominent player in the
pediatric drops category over the last several years, and we look forward to
adding DEXO's sales resources to increase the Accuhist share of this major
category.'

For further information:

BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court

About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a vertically integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGEL(TM) polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to
www.bioprogress.com

About Tiber Laboratories, LLC

Tiber Laboratories LLC is a Georgia, USA corporation focused on the development
and distribution of prescription products to the pediatric and primary care
markets. The therapeutic focus of Tiber Laboratories has been in the areas of
respiratory management and dermatology. However, there are other markets
currently under consideration. Tiber is lead by a team of highly experienced
industry veterans. They have been active in the acquisition of several
recognized brands including the Accuhist(R), Endal(R), Histex(TM), and
Viravan(TM). Tiber will be launching several new products through their own
sales forces as well as through partnership.


BioP is a transformed company and is going about it's business quietly; building an interesting product base and portfolio. RT doing a good job. Preliminary year end results due on the 19 April. Long awaited news of a big pharma deal cant be far away! Keep an eye on them.

Good News Today?

Walrus

Actually, that was a mindless post to see if my sign on worked.

That said I do expect significant news in the short term. All one has to do is go backwards from a product launch last qtr 2007 and BPRG simply have to have news in the wing.

Walrus

ttt

;-0

Not the result some wanted, but with a mkt cap of around 90m and less than zero profits, what else can be expected?

They haven't given us a product buy for EXGEL and really for most of us that's what we have been led to believe was the lynchpin for the future? Mkt cap might halve from here and not many would be surprised? 'Till they give us the nod on XGEL that is.

What happened to the millions of rampers who use to call me all sorts of names on the bprg threads ?

Did they all go bust ?

No Dill bought at 28p and holding, and holding. I think there is lot further to go!








And it is up 8-)


Nos dda i chwi.

News Article
Launch of new edible film strip product line "Faststrips in US
18/05/2007


London, UK, 18 May 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company, today announces the launch in the US of a range of fast release Soluleaves film strip products. The range is marketed under the brand 'Fast Strips' (www.faststrips.com) and will be managed within the Nutrifilms marketing division of the Company"s subsidiary Dexo US. The product range is available to retailers and is initially being introduced to US retailers at the Chain Drug Marketing Association Virtual Trade Show which runs to 31 May 2007.

The Fast Strips line of products consists of two brand families. The first is the Stay brand family which is targeted at a traditional grocery or drugstore customer. The second family, the Premium brand family, is a group of individual brands that will be targeted towards specific demographic groups and are premium priced. The initial product launch consists of six products in the Stay family and seven products in the Premium family. Fast Strips will be introduced at smaller retail outlets initially and new products will be added to the line on a quarterly basis.

Richard Trevillion, CEO said:

The Fast Strips launch demonstrates the breadth and depth of BioProgresss pipeline. In addition to the Companys prescription only range, the Group now has a multi-channel offering in one of the fastest growing categories in the US domestic market.

For further information:

Share price up about 5.14% with increased volume based on the above information.

Interesting to see next week.

Will this ever be a quid again?

Seriously, they seem to bring out a stream of decent news. You'd think it would stick more than the smellier stuff these days. Hmm.

BA, I think so, but it has to breakout of the present side way trading and break through its 75p resistance level.

The projected results should support future higher price.

The majority of analyst are positive.

I think (hope) it will fly over the next few months unless stalled by overall market retracement.

Sentiment is a strong driver in stock markets unfortunately Fred.

It seems to be bad around here still.

You don't think they may takeover SEO again. 8-)

News Article
Acquisition of PharmaHerb Limited
21/05/2007


London, UK, 21 May 2007: BioProgress (AIM: BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company today announces the acquisition of PharmaHerb Limited ("PharmaHerb), a UK-based vitamin and nutritional business. The consideration for the acquisition was 600,000 which has been settled by 150,000 cash and the issue of 694,981 ordinary shares of the Company with a value of 450,000. Application will be made for these new ordinary shares to be admitted to trading on the AIM market of the London Stock Exchange. It is expected that dealings will commence on 24 May 2007.


PharmaHerb is a specialist 'Over-the-Counter' (OTC) products company, whose core activities include product formulation, manufacturing and packaging. The acquisition includes PharmaHerb"s Kudos range of brands together with its sales and marketing capabilities. The Kudos brand is a premier label business focused on the promotion of vitamin and nutritional products through established and diversified distribution channels. These distribution channels include niche health shops, pharmacies as well as supermarket chains. The business also has a direct-to-consumer internet sales capability (www.kudosvitamins.com).

The acquisition of PharmaHerb creates an OTC platform for the Company with established sales and marketing channels which will allow BioProgress to directly market its own OTC ranges into its domestic market. Pharmaherb acquired the assets of Kudos in March 2007 which included packaging equipment, stock, formulations, intellectual property as well as sales and marketing agreements and established channels to the OTC consumer market. The sales of Pharmaherb are negligible (2006 sales of Kudos were 255,000 and the business invested approximately 1m in capital for assets and infrastructure growth), however, the assets represent an operating infrastructure and thus a low cost entry into the UK market. BioProgress expects to utilise these assets immediately to create strong organic growth. Combining the Kudos and Dexo product ranges will provide a broader product portfolio to further develop and expand the acquired sales and distribution capabilities. In particular the business will be used as a base to launch future UK Soluleaves, Meltums and other XGEL enhanced OTC products.

The acquisition is analogus to that of DMPL earlier in the year and will provide a significant distribution channel for the MINCI DIET product range as well as supporting the co-promotion of SlimThru obtained through a partnership agreement with Melbrosin International, announced earlier this year.

Richard Trevillion, Chief Executive Officer said:

The acquisition of PharmaHerb Limited and the Kudos brand are an important step as a launch pad for our own XGEL OTC products and to generate revenues within the UK market place. The acquisition further strengthens our position and reflects our drive into the growing niche branded OTC market. The established distribution channels that come with this acquisition allows us greater and more rapid market access for our growing product portfolio.

For further information:



BioProgress Plc
+ 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO


Buchanan Communications
+ 44 (0) 20 7466 5000

Rebecca Skye Dietrich

Mark Court



About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

How times change. 3 years ago this was the stepping stone to world domination. It brings a wry smile to one's face. ;-))



BioProgress PLC
29 May 2007


For Immediate Release 29 May 2007


BioProgress plc ('BioProgress' or the 'Company')
Intention to delist from NASDAQ, deregister and terminate SEC reporting
obligations

London, UK, (29 May 2007): BioProgress (AIM: BPRG; NASDAQ: BPRG), the specialty
pharma and healthcare company today announces that it will delist its Amercian
Depositary Receipts ('ADRs') from The NASDAQ Stock Market and deregister and
terminate the Company's reporting obligations under the U.S. Securities Exchange
Act of 1934 (the 'Exchange Act'). The Company's Ordinary Shares will continue to
trade on London's AIM.

The Company has provided written notice to NASDAQ of its intention to delist and
intends to file a Form 25 with the SEC on 8 June 2007 to effect the delisting.
The Company reserves the right to delay the filing of the Form 25 or withdraw
the Form 25 for any reason prior to its effectiveness. The delisting is expected
to take effect on 18 June 2007 at which point the Company will file a Form 15F
with the SEC to deregister and terminate its reporting obligations under the
Exchange Act. The deregistration is expected to become effective on 17 September
2007, by operation of law. The Company reserves the right to delay the filing of
the Form 15F or withdraw the Form 15F for any reason prior to its effectiveness.

The decision to delist from NASDAQ, deregister and terminate the Company's
reporting obligations under the Exchange Act has been made due to the burdensome
costs of compliance with the SEC rules and in particular the Section 404
requirements of the Sarbanes-Oxley Act of 2002. The Company believes that the
cost of compliance outweighs the limited benefits and trading in the company's
shares for a company like BioProgress and the cash saved can be put to greater
use in other parts of the business.

The Company expects to maintain its ADR facility with JPMorgan Chase Bank, N.A.,
and to amend its Deposit Agreement with JPMorgan Chase Bank, N.A., to reflect
its deregistration and allow its ADR's to trade on the over-the-counter (OTC)
market in the United States. BioProgress expects to continue to publish its
Results and other documents and communications in accordance with Exchange Act
Rule 12g3-2 on its Web site, located at www.bioprogress.com.

Richard Trevillion, Chief Executive Officer commented:
'At this stage of the Company's development there are limited benefits of a dual
listing and the costs of maintaining the NASDAQ listing have increased
significantly over the last 18 months. The cost savings can be utilised to
accelerate the growth of the business, particularly in the United States, which
continues to be an important market for the business.'

For further information:

BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court

Just to keep Dil happy, but it is an impressive list.

LSE 61.66 p +2.41
Nasdaq 11.61 $ 0.00Latest News News Alert Downloads Media Relations About Us Pharma Product Development Enabling Systems Production Investor Relations Media Relations Contact Us Home> Media> Latest News> ArticleNews Article
Proprietary Product Development Update
31/05/2007



London, UK, 31 May 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company, today announces an update on its product development program.


BioProgress has nine integrated enabling drug delivery technologies with pharmaceutical and healthcare applications. The Company has in development over 30 patent protected products using these core enabling technologies. The developments are classed into three main categories

1. OTC and Nutritional Products

2. Line extensions for acquired Pharmaceutical Brands

3. Innovative Products suitable for out-licensing or for sale by Dexo BioPharm

1. OTC and Nutritional Products

The Company has launched a range of Soluleaves nutritional products in the United States and Europe. In addition, in the OTC pharmaceutical sector, the Company has developed a range of Soluleaves products for launch initially through Dexo US. The products include respiratory drugs, cough / cold and sore throat products. These products do not require pre-FDA approval and will be marketed throughout 2007. Development work is carried out at the Company's facilities in Cambridge, UK and in Tampa, USA. The range includes the following:



Technology Development Phase

DBP130 Anti-Diarrhoea Soluleaves Pre-registration
DBP147 Local Anaesthetic Soluleaves Launch phase - US
DBP211 Decongestant Soluleaves Pre-registration
DBP214 Anti-histamine Soluleaves Pre-registration
DBP216 Analgesic TabWrap Scale Up
DBP310 Analgesic - basic FastWrap Pre-registration
DBP312 Analgesic - combination FastWrap Pre-registration
DBP314 Analgesic Cold & flu FastWrap Pre-registration


The Global OTC market for analgesics and cough/cold products is worth $16.7 Billion per annum. Similar new novel patented pharmaceutical technologies can achieve sales penetration rates of approximately one percent of the relevant market share.

2. Line Extensions for acquired Pharmaceutical Brands

BioProgress has acquired a number of branded medicines suitable for immediate extension utilizing one of the Company"s enabling systems. The main developments in this area are:

Product Territory Launch

DBP213 Cough Ah-Chew extension USA 2007
DBP215 Cough & Cold Ah-Chew extension USA 2007
DBP272 Gastric Reflux -Combo RocGe EU 2008
DBP274 Gastric Reflux - Basic RocGel Global 2008/9
DBP276 Gastric Reflux - Chewable RocGel Global 2008/9


The Ah-Chew line extensions use Soluleaves technology and will be the first oral thin film within the US DESI prescription market. The line extensions for RocGel use the liquid SoluPol technology, as well as a chewable tablet, and are expected to be a core driver for pan-European sales within the gastro-intestinal market. The SoluPol range of products has been developed by the Cambridge Development team.

3. Key Innovative Developments

The Companys core new development includes the following:-

DBP117 Anti-Migraine

The Development team has been able to overcome significant technical challenges to place an anti-migraine drug of a class of compound known as a triptan into an oral film strip. The triptan market includes brands such as Imitrex (GSK) and Zomig (AstraZeneca) and is worth $3.1 billion in 2007 (Datamonitor) growing at 3.1% per annum. A number of these products are converting from Prescription to Over the Counter use which is expected to expand the market.

The product has passed the initial formulation phase and is due to commence scale-up manufacturing trials in H2 2007. The product is planned for submission to US and EU regulatory authorities during 2008. It is expected that DBP117 will achieve peak sales revenues of 1 to 1.5 percent of the Global triptan market share per annum.

DBP118 Anti-emesis

BioProgress has developed a product for anti-emesis which has been induced by cancer therapy. The category of medicines is called 5-HT3 antagonists, such as Zofran (GSK) and Kytril (Roche), have become the mainstay of the treatment of oncology induced nausea.

The Company has formulated a DBP118 using the Oradisc technology, owned by Uluru Inc. The product uses a buccal disc that can dissolve gradually over time, allowing for the sustained release of the active drug.

It is expected that the product will enter into pharmacokinetic studies during 2008 with the product being filed using the NDA 505 (b) (2) regulatory pathway. The Company is expecting peak sales revenues to be in the region of $32-40m per annum.

DBP121 Smoking Cessation Product

BioProgress has developed a new concept in smoking cessation. Whilst lozenges and microtabs take 10-30 minutes to deliver their nicotine content, a cigarette typically will deliver the effects of its nicotine in seconds. Current therapies do not mimic this "high and therefore smokers find it difficult to reduce the number of cigarettes accordingly. The current global smoking cessation market is estimated to be $2.3 billion (Datamonitor)

The Company completed its first volunteer study in April 2007 as an open assessment study in volunteer smokers. This study showed a marked decrease in cravings using DBP121. Along with positive taste and consumer acceptability information, this data has been instrumental in the Companys discussions with several global partners. BioProgress is currently assessing all of the potential partners from global to regional partners in order to extract the maximum benefit for the Company.

From detailed market analyses and from other launches of new nicotine replacement dosage forms, BioProgress anticipates that DBP121has a peak sales potential of $150 to 200m per annum within the smoking cessation market.

DBP167 Analgesic

DBP167 is a series of developments using a novel form of ibuprofen in conjunction with polymer technology. The development is focusing on the requirement to deliver analgesia significantly quicker into the blood stream than traditional pharmaceutical tablets. Published data shows that standard paracetamol type of analgesics can take 40-90 minutes before the patient is able to see a noticeable reduction in pain. BioProgresss product has demonstrated impact in only a few minutes, anything from a simple headache, migraine or breakthrough pain can be effectively and quickly treated.

SoluPol liquids, Meltums (melt in the mouth), NRobe and FastWrap versions are all scheduled for development as analgesic indications along with a novel sachet formulation integrating decongestants for line extensions into the Ah-Chew franchise.

The global OTC market for analgesics alone is currently $6.2 billion with the cough-cold market being $10.5 billion. With the addition of the prescription analgesic market, BioProgress believes that it has a unique marketing advantage over the main competitors. The products will be promoted into the prescription market as well as the OTC market and will become a cornerstone of the BioProgress core product developments.

DBP167 will enter regulatory submission in H2 2007, with the further developments progressing through formulation and scale-up.

With the target OTC market being in excess of $16 billion, the company estimates that its innovative prescription and OTC strategy would lead to a 1 - 1.5 % market share of the major pharmaceutical markets.

Steve Martin, Chief Development Officer said:

BioProgress has made significant progress over the last year converting its enabling technologies into tangible product developments that meet consumer and partner expectations. We have launched three new technologies, EntWrap, FastWrap and Meltums. Each of these technologies has been well received by potential partners and as the Company has progressed in its developments, the data accumulated has been instrumental in increasing the partner interest.

The Development team is working on a number of confidential product projects with other pharmaceutical companies using the full range of enabling technologies. With revenues currently being received from its restructured NRobe technology licence agreement, the Company is in a strong position to deliver its own technologies to the consumer market.

Product launches are scheduled throughout 2007 and beyond, a healthy pipeline is essential for the future growth and profitability of BioProgress. The Development Team has worked tirelessly to create our vision of medicines that act quickly and are easy to take.

For further information:



BioProgress Plc
+ 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO


Buchanan Communications
+ 44 (0) 20 7466 5000

Rebecca Skye Dietrich

Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Companys filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.










Privacy Statement | Disclaimer | Trade Mark Statement | Accessibility Statement | Sitemap | Glossary

Ta Fred ... much appreciated :-)